{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:06:55Z","timestamp":1783123615528,"version":"3.54.6"},"reference-count":286,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":1800,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2007,2]]},"abstract":"<jats:p>Limited established treatment options exist for the treatment of serious, invasive infections caused by multidrug\u2010resistant <jats:italic>Staphylococcus aureus<\/jats:italic>, most notably nosocomially acquired methicillin\u2010resistant <jats:italic>S. aureus<\/jats:italic> (MRSA). Although vancomycin represents the gold standard for therapy of such invasive infections, reports of increasing in vitro resistance to vancomycin, combined with reports of clinical failures (with this and other antistaphylococcal agents), underscore the need for alternative therapies. Older agents with favorable in vitro activity available in both oral and intravenous dose forms include trimethoprim\u2010sulfamethoxazole and clindamycin. Limited clinical data exist to support their routine use as initial therapy in the treatment of invasive disease. However, these and other options (e.g., tetracyclines) are being reexplored in the setting of increasing concern over MRSA acquired in the community setting. Newer treatment options for MRSA include linezolid, quinupristin\u2010dalfopristin, daptomycin, and tigecycline. With the exception of linezolid, these newer agents require intravenous administration. Combination therapy may be considered in select invasive diseases refractory to standard monotherapies. These diseases include infections such as endocarditis, meningitis, and prosthetic device infections. Additional alternatives to vancomycin are under clinical investigation. Those in later stages of development include oritavancin, dalbavancin, telavancin, and ceftobiprole.<\/jats:p>","DOI":"10.1592\/phco.27.2.227","type":"journal-article","created":{"date-parts":[[2007,1,25]],"date-time":"2007-01-25T12:41:39Z","timestamp":1169728899000},"page":"227-249","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Emerging Options for Treatment of Invasive, Multidrug\u2010Resistant <i>Staphylococcus aureus<\/i> Infections"],"prefix":"10.1002","volume":"27","author":[{"given":"Richard H.","family":"Drew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","volume-title":"Frequency of occurrence and antimicrobial susceptibility of bacterial isolates causing bloodstream infections worldwide: report from 8 years of the SENTRY antimicrobial surveillance program (1997\u20132004) [abstr]","author":"Sader HS","year":"2005"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/1476-0711-5-2"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/345436"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/421946"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/430788"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-5-200603070-00005"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/502522"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2005.02.007"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/367653"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000201885.57697.21"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/491709"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/491714"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0012-3692(15)33412-7"},{"key":"e_1_2_1_15_2","unstructured":"Food and Drug Administration.Cubicin (daptomycin for injection) for the treatment ofStaphylococcus aureusbacteremia including those with known or suspected infective endocarditis. FDA briefing document for Antiinfective Advisory Committee March 2006. Available fromhttp:www.fda.govohrmsdocketsac06briefing20064209B1_02_01\u2010FDA\u2010Background.pdf. Accessed July 20 2006."},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/491713"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00776-005-0968-7"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443130-00005"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/491712"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.4.539"},{"key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/jcm.20.4.791-796.1984","article-title":"Antimicrobial agent susceptibility patterns of bacteria in hospitals from 1971 to 1982","volume":"20","author":"Atkinson BA","year":"1984","journal-title":"J Clin Microbiol"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/499404"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki486"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.1.135"},{"key":"e_1_2_1_25_2","first-page":"765","article-title":"Staphylococcus aureus with reduced susceptibility to vancomycin: United States, 1997","volume":"46","author":"Centers for Disease Control and Prevention","year":"1997","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199902183400701"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0805.010387"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2001.tb143681.x"},{"key":"e_1_2_1_29_2","first-page":"1165","article-title":"Staphylococcus aureus with reduced susceptibility to vancomycin: Illinois, 1999","volume":"48","author":"Centers for Disease Control and Prevention","year":"2000","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199902183400704"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04403-2"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.Supplement_1.S74"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3040-3045.2003"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1086\/381093"},{"key":"e_1_2_1_35_2","first-page":"565","article-title":"Staphylococcus aureus resistant to vancomycin: United States, 2002","volume":"51","author":"Centers for Disease Control and Prevention","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_1_36_2","first-page":"902","article-title":"Public health dispatch: vancomycin\u2010resistant Staphylococcus aureus\u2014Pennsylvania, 2002","volume":"51","author":"Centers for Disease Control and Prevention","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.22.2976"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0702.010204"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1086\/322693"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2004.10.011"},{"key":"e_1_2_1_41_2","first-page":"336","article-title":"Antimicrobial susceptibility and clonal relatedness between community\u2010 and hospital\u2010acquired methicillin\u2010resistant Staphylococcus aureus from blood cultures","volume":"44","author":"Jung SI","year":"2006","journal-title":"J Microbiol"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg130"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.5.1689-1693.2003"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000207403.67197.cc"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1086\/346207"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0706.010618"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0804.010245"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.22.12.983.33599"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf184"},{"key":"e_1_2_1_50_2","first-page":"172","article-title":"Chemotherapy of acute bone and joint infections","volume":"62","author":"Bajpai J","year":"1977","journal-title":"Int Surg"},{"key":"e_1_2_1_51_2","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1128\/AAC.42.12.3086","article-title":"Ambulatory treatment of multi\u2010drug resistant Staphylococcus\u2010infected orthopedic implants with high\u2010dose oral co\u2010trimoxazole (trimethoprim\u2010sulfamethoxazole)","volume":"42","author":"Stein A","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-5-390"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.2165\/00148581-200507020-00002"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001432-200306000-00014"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.4.1.91"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1086\/497143"},{"key":"e_1_2_1_57_2","unstructured":"GorwitzRJ JerniganDB PowersJH Jernigan JA for the Participants in the CDC\u2010Convened Experts' Meeting on Management of MRSA in the Community.Strategies for clinical management of MRSA in the community: summary of an experts' meeting convened by the Centers for Disease Control and Prevention 2006. Available fromhttp:www.cdc.govncidoddhqpar_mrsa_ca.html. Accessed July 20 2006."},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.4.1410-1415.2003"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.11.3651-3652.2003"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.44.1.108-118.2006"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043252"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1108.050116"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2004.09.002"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1086\/500060"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl017"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-5-200603070-00006"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.06.013"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1086\/500621"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1204.050960"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(02)00371-1"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.01.004"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000073163.37519.ee"},{"key":"e_1_2_1_73_2","first-page":"E\u20101748","volume-title":"Activity of daptomycin, clindamycin, linezolid, teicoplanin, trimethoprim\u2010sulfamethoxazole and vancomycin against community and hospital\u2010associated methicillin\u2010resistant Staphylococcus aureus [abstr]","author":"Tsuji BT","year":"2005"},{"key":"e_1_2_1_74_2","unstructured":"HagemanJ Como\u2010SabettiK RegoV.A multistate study of the epidemiology of community\u2010onset methicillin\u2010resistantStaphylococcus aureus. Presented at the 40th annual meeting of the Infectious Diseases Society of America Chicago October 2427 2002."},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000207404.50143.1e"},{"key":"e_1_2_1_76_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.7.1267"},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.10.4740-4744.2003"},{"key":"e_1_2_1_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2003.11.008"},{"key":"e_1_2_1_79_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200210000-00005"},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.1086\/377501"},{"key":"e_1_2_1_81_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.6.2283-2288.2005"},{"key":"e_1_2_1_82_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/7.suppl_A.67"},{"key":"e_1_2_1_83_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800670207"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200206000-00010"},{"key":"e_1_2_1_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(02)00540-0"},{"key":"e_1_2_1_86_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.23.3.450"},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.165564"},{"key":"e_1_2_1_88_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.19.1537"},{"key":"e_1_2_1_89_2","first-page":"F\u20101860","volume-title":"Optimization and application of in vitro models for evaluation of antimicrobial efficacy against staphylococcal biofilms [abstr]","author":"Roche ED","year":"2005"},{"key":"e_1_2_1_90_2","first-page":"C2","volume-title":"Changing patterns of bacterial pathogens and their antimicrobial susceptibility profiles in patients hospitalized with pneumonia: report from the SENTRY antimicrobial surveillance program [abstr]","author":"Fritsche TR","year":"2003"},{"key":"e_1_2_1_91_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-97-4-496"},{"key":"e_1_2_1_92_2","doi-asserted-by":"publisher","DOI":"10.1086\/367661"},{"key":"e_1_2_1_93_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh474"},{"key":"e_1_2_1_94_2","doi-asserted-by":"publisher","DOI":"10.1086\/429628"},{"key":"e_1_2_1_95_2","first-page":"C2","volume-title":"Tigecycline in vitro activity against Staphylococcus aureus and Enterococcus strains resistant to other drugs in the T.E.S.T. program: United States, 2004\u20132005 [abstr]","author":"Johnson J","year":"2005"},{"key":"e_1_2_1_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2005.06.001"},{"key":"e_1_2_1_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.otohns.2005.03.003"},{"key":"e_1_2_1_98_2","doi-asserted-by":"publisher","DOI":"10.1086\/367662"},{"key":"e_1_2_1_99_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2606-2612.2002"},{"key":"e_1_2_1_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(01)00334-0"},{"key":"e_1_2_1_101_2","first-page":"C2","volume-title":"First annual report from the worldwide AAAPS oxazolidinone resistance and usage surveillance program [abstr]","author":"Jones RN","year":"2003"},{"key":"e_1_2_1_102_2","first-page":"C2","volume-title":"In vitro activity of linezolid against key gram\u2010positive organisms isolated in the United States: results of the LEADER 2004 surveillance program [abstr]","author":"Draghi DC","year":"2005"},{"key":"e_1_2_1_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2004.12.013"},{"key":"e_1_2_1_104_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki437"},{"key":"e_1_2_1_105_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg457"},{"key":"e_1_2_1_106_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg104"},{"key":"e_1_2_1_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05410-1"},{"key":"e_1_2_1_108_2","doi-asserted-by":"publisher","DOI":"10.1086\/345368"},{"key":"e_1_2_1_109_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-10-200311180-00017"},{"key":"e_1_2_1_110_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.11.008"},{"key":"e_1_2_1_111_2","doi-asserted-by":"publisher","DOI":"10.1086\/318486"},{"key":"e_1_2_1_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80118-2"},{"key":"e_1_2_1_113_2","doi-asserted-by":"publisher","DOI":"10.1086\/340353"},{"key":"e_1_2_1_114_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.6.2260-2266.2005"},{"key":"e_1_2_1_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2004.08.045"},{"key":"e_1_2_1_116_2","doi-asserted-by":"publisher","DOI":"10.1086\/500139"},{"key":"e_1_2_1_117_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2005.01.011"},{"key":"e_1_2_1_118_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki355"},{"key":"e_1_2_1_119_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-2-200301210-00015"},{"key":"e_1_2_1_120_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161040-00008"},{"key":"e_1_2_1_121_2","doi-asserted-by":"publisher","DOI":"10.1086\/338403"},{"key":"e_1_2_1_122_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.6.1824-1831.2003"},{"issue":"2","key":"e_1_2_1_123_2","first-page":"II45","article-title":"Safety and tolerability of linezolid","volume":"51","author":"French G","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_1_124_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199903)60:3<249::AID-AJH20>3.0.CO;2-H"},{"key":"e_1_2_1_125_2","doi-asserted-by":"publisher","DOI":"10.1086\/498509"},{"key":"e_1_2_1_126_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1599-1602.2006"},{"key":"e_1_2_1_127_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-005-4057-9"},{"key":"e_1_2_1_128_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000201313.24970.b8"},{"key":"e_1_2_1_129_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.11.047"},{"key":"e_1_2_1_130_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200301023480123"},{"key":"e_1_2_1_131_2","doi-asserted-by":"publisher","DOI":"10.1086\/378895"},{"key":"e_1_2_1_132_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E523"},{"key":"e_1_2_1_133_2","doi-asserted-by":"publisher","DOI":"10.1086\/503839"},{"key":"e_1_2_1_134_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.3.263.34198"},{"key":"e_1_2_1_135_2","first-page":"317","article-title":"Early switch and early discharge opportunities in intravenous vancomycin treatment of suspected methicillin\u2010resistant staphylococcal species infections","volume":"9","author":"Parodi S","year":"2003","journal-title":"J Manag Care Pharm"},{"key":"e_1_2_1_136_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200405-644ST"},{"key":"e_1_2_1_137_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2003.03.006"},{"key":"e_1_2_1_138_2","first-page":"180","article-title":"Guidelines for the management of intravascular catheter\u2010related infections","volume":"24","author":"Mermel LA","year":"2001","journal-title":"J Intraven Nurs"},{"key":"e_1_2_1_139_2","doi-asserted-by":"publisher","DOI":"10.1086\/345744"},{"key":"e_1_2_1_140_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl219"},{"key":"e_1_2_1_141_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-004-3029-9"},{"key":"e_1_2_1_142_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.10.2880-2882.2000"},{"key":"e_1_2_1_143_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.7.1419"},{"key":"e_1_2_1_144_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2004.06.016"},{"key":"e_1_2_1_145_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.6.847"},{"key":"e_1_2_1_146_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.6.931"},{"key":"e_1_2_1_147_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)80002-3"},{"key":"e_1_2_1_148_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.6.783"},{"key":"e_1_2_1_149_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00121-7"},{"key":"e_1_2_1_150_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.4.1020-1027.1998"},{"key":"e_1_2_1_151_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl235"},{"key":"e_1_2_1_152_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.5.775"},{"key":"e_1_2_1_153_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80028-X"},{"key":"e_1_2_1_154_2","volume-title":"Synercid\u00ae (quinupristin\u2010dalfopristin) product information","author":"Monarch Pharmaceuticals.","year":"2003"},{"key":"e_1_2_1_155_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh546"},{"key":"e_1_2_1_156_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.8.2538-2544.2003"},{"key":"e_1_2_1_157_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2595-2601.2002"},{"key":"e_1_2_1_158_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.12.3447-3450.2000"},{"key":"e_1_2_1_159_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.5.1598-1603.2003"},{"key":"e_1_2_1_160_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg337"},{"key":"e_1_2_1_161_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.1062-1066.2000"},{"key":"e_1_2_1_162_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.6.1919-1922.2001"},{"key":"e_1_2_1_163_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(00)00164-4"},{"key":"e_1_2_1_164_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.3.467"},{"key":"e_1_2_1_165_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.2.219"},{"key":"e_1_2_1_166_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.4.563"},{"key":"e_1_2_1_167_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2003.12.014"},{"key":"e_1_2_1_168_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2004.04.006"},{"key":"e_1_2_1_169_2","volume-title":"Cubicin (daptomycin for injection) product information","author":"Cubist Pharmaceuticals.","year":"2003"},{"key":"e_1_2_1_170_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg288"},{"key":"e_1_2_1_171_2","doi-asserted-by":"publisher","DOI":"10.1086\/504084"},{"key":"e_1_2_1_172_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1581-1585.2006"},{"key":"e_1_2_1_173_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.3.1079-1082.2006"},{"key":"e_1_2_1_174_2","first-page":"A\u20101268","volume-title":"Clinical strains of Staphylococcus aureus from 1987 and 1989 with reduced glycopeptide susceptibility resulting from teicoplanin exposure [abstr]","author":"Rybak M","year":"2002"},{"key":"e_1_2_1_175_2","first-page":"C1","volume-title":"In vitro activity of daptomycin against multidrug\u2010resistant Staphylococcus aureus [abstr]","author":"Sahm DF","year":"2003"},{"key":"e_1_2_1_176_2","first-page":"C1","volume-title":"Killing activity of daptomycin against vancomycin intermediate Staphylococcus aureus (VISA) and hetero\u2010VISA [abstr]","author":"Howe RA","year":"2003"},{"key":"e_1_2_1_177_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.12.3960-3963.2003"},{"key":"e_1_2_1_178_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1532-5415.2002.50377.x"},{"key":"e_1_2_1_179_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01491-05"},{"key":"e_1_2_1_180_2","doi-asserted-by":"publisher","DOI":"10.1086\/428616"},{"key":"e_1_2_1_181_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.44.2.655-656.2006"},{"key":"e_1_2_1_182_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.44.2.595-597.2006"},{"key":"e_1_2_1_183_2","doi-asserted-by":"publisher","DOI":"10.1086\/502688"},{"key":"e_1_2_1_184_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.1.41.34802"},{"key":"e_1_2_1_185_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464040-00009"},{"key":"e_1_2_1_186_2","doi-asserted-by":"publisher","DOI":"10.1086\/420818"},{"key":"e_1_2_1_187_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh531"},{"key":"e_1_2_1_188_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X74961"},{"key":"e_1_2_1_189_2","volume-title":"Data on file","author":"Cubist Pharmaceuticals.","year":"2003"},{"key":"e_1_2_1_190_2","doi-asserted-by":"publisher","DOI":"10.1086\/430352"},{"key":"e_1_2_1_191_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.4.523"},{"key":"e_1_2_1_192_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.2948-2953.2000"},{"key":"e_1_2_1_193_2","first-page":"L\u2010737","volume-title":"Comparison of efficacy and safety of daptomycin versus semi\u2010synthetic penicillin and vancomycin in patients with complicated skin and skin structure infections [abstr]","author":"Campanaro E","year":"2003"},{"key":"e_1_2_1_194_2","first-page":"E\u20101743","volume-title":"Bactericidal action of daptomycin against non\u2010dividing Staphylococcus aureus [abstr]","author":"Mascio CTM","year":"2005"},{"key":"e_1_2_1_195_2","first-page":"E\u2010809","volume-title":"Activity of daptomycin and tigecycline against clinical isolates causing catheter\u2010related methicillin\u2010resistant Staphylococcus aureus embedded in biofilm [abstr]","author":"Hachem R","year":"2005"},{"key":"e_1_2_1_196_2","first-page":"A\u20101387","volume-title":"Pharmacokinetics and safety of single\u2010dose daptomycin in subjects with graded renal insufficiency and end stage renal disease [abstr]","author":"Sica DA","year":"2002"},{"key":"e_1_2_1_197_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464010-00005"},{"key":"e_1_2_1_198_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.2.505-510.2006"},{"key":"e_1_2_1_199_2","first-page":"169","volume-title":"In vitro activity of GAR\u2010936 against vancomycin resistant enterococci, methicillin\u2010resistant Staphylococcus aureus and penicillin\u2010resistant pneumococci [abstr]","author":"Piper KE","year":"2000"},{"key":"e_1_2_1_200_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg289"},{"key":"e_1_2_1_201_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2005.06.001"},{"key":"e_1_2_1_202_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2005.05.002"},{"key":"e_1_2_1_203_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2005.05.003"},{"key":"e_1_2_1_204_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2005.05.004"},{"key":"e_1_2_1_205_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2005.05.005"},{"key":"e_1_2_1_206_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2005.06.004"},{"key":"e_1_2_1_207_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2004.07.007"},{"key":"e_1_2_1_208_2","first-page":"E\u2010322","volume-title":"Baseline tigecycline activity against current and geographically diverse Staphylococcus aureus strains exhibiting key resistance phenotypes [abstr]","author":"Draghi DC","year":"2005"},{"key":"e_1_2_1_209_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.22.17.1517.34117"},{"key":"e_1_2_1_210_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.943-949.2000"},{"key":"e_1_2_1_211_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2005.17.Supplement-1.12"},{"key":"e_1_2_1_212_2","first-page":"A\u201022","volume-title":"Comparative pharmacodynamic activity of tigecycline (GAR\u2010936) against quinolone\u2010resistant S. pneumoniae, methicillin\u2010resistant S. aureus and vancomycin\u2010resistant enterococci [abstr]","author":"Garrison MW","year":"2005"},{"key":"e_1_2_1_213_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.15.2.155"},{"key":"e_1_2_1_214_2","doi-asserted-by":"publisher","DOI":"10.1086\/431676"},{"key":"e_1_2_1_215_2","doi-asserted-by":"publisher","DOI":"10.1086\/431675"},{"key":"e_1_2_1_216_2","volume-title":"Tygacil\u00ae (tigecycline) prescribing information","author":"Wyeth Pharmaceuticals.","year":"2005"},{"key":"e_1_2_1_217_2","first-page":"A\u20101403","volume-title":"Pharmacokinetics, safety and tolerability of tigecycline (GAR\u2010936) in healthy Japanese males [abstr]","author":"Sesoko S","year":"2002"},{"key":"e_1_2_1_218_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.220-229.2005"},{"key":"e_1_2_1_219_2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1128\/AAC.43.3.717","article-title":"Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin\u2010sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin\u2010intermediate Staphylococcus aureus by time\u2010kill curve methods","volume":"43","author":"Hershberger E","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_220_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.2991-2998.2000"},{"key":"e_1_2_1_221_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2497"},{"key":"e_1_2_1_222_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.10.4016-4019.2004"},{"key":"e_1_2_1_223_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.7.1549"},{"key":"e_1_2_1_224_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003086-199611000-00025"},{"key":"e_1_2_1_225_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.4.1122-1124.2002"},{"key":"e_1_2_1_226_2","doi-asserted-by":"publisher","DOI":"10.1086\/314035"},{"key":"e_1_2_1_227_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-4179(99)00045-5"},{"key":"e_1_2_1_228_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-9-674"},{"key":"e_1_2_1_229_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.suppl_1.33"},{"key":"e_1_2_1_230_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540110077245"},{"key":"e_1_2_1_231_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D323"},{"key":"e_1_2_1_232_2","first-page":"413","article-title":"Rapid response of methicillin\u2010resistant Staphylococcus aureus infections to quinupristin\u2010dalfopristin plus vancomycin in patients failing vancomycin [abstr]","volume":"22","author":"Moise PA","year":"2002","journal-title":"Pharmacotherapy"},{"key":"e_1_2_1_233_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-002-2117-y"},{"key":"e_1_2_1_234_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(02)00360-7"},{"key":"e_1_2_1_235_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.7.1747"},{"key":"e_1_2_1_236_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.5.1394-1396.2000"},{"key":"e_1_2_1_237_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.302-308.2005"},{"key":"e_1_2_1_238_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.2871-2875.2004"},{"key":"e_1_2_1_239_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.34.5.559"},{"key":"e_1_2_1_240_2","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(89)90022-9"},{"key":"e_1_2_1_241_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/13.suppl_C.17"},{"key":"e_1_2_1_242_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.5.1370-1374.2000"},{"key":"e_1_2_1_243_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.2.179"},{"key":"e_1_2_1_244_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.5.1700-1706.2003"},{"key":"e_1_2_1_245_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.1.58.34808"},{"key":"e_1_2_1_246_2","first-page":"C1","volume-title":"Oritavancin demonstrates potent in vitro activity against clinically relevant isolates of staphylococci [abstr]","author":"Blosser RS","year":"2003"},{"key":"e_1_2_1_247_2","first-page":"E\u20101452","volume-title":"Activity of oritavancin against clinical isolates of Staphylococcus aureus collected from blood specimens in the U.S [abstr]","author":"Critchley IA","year":"2002"},{"key":"e_1_2_1_248_2","first-page":"3","volume-title":"Equivalence of shorter course therapy with oritavancin vs vancomycin\/cephalexin in complicated skin\/skin structure infections [abstr]","author":"Wasilewski MM","year":"2001"},{"key":"e_1_2_1_249_2","first-page":"L\u2010739a","volume-title":"Phase 3 trial comparing 3\u20137 days of oritavancin vs 10\u201314 days of vancomycin\/cephalexin in the treatment of patients with complicated skin and skin structure infections [abstr]","author":"Giamarellou H","year":"2003"},{"key":"e_1_2_1_250_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki005"},{"key":"e_1_2_1_251_2","doi-asserted-by":"publisher","DOI":"10.1586\/14789072.2.6.845"},{"key":"e_1_2_1_252_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh401"},{"key":"e_1_2_1_253_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.770-772.2005"},{"key":"e_1_2_1_254_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2004.01051.x"},{"key":"e_1_2_1_255_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2003.09.004"},{"key":"e_1_2_1_256_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2005.08.015"},{"key":"e_1_2_1_257_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00286-06"},{"key":"e_1_2_1_258_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.3.1061-1064.2004"},{"key":"e_1_2_1_259_2","doi-asserted-by":"publisher","DOI":"10.1086\/379015"},{"key":"e_1_2_1_260_2","doi-asserted-by":"publisher","DOI":"10.1086\/497271"},{"key":"e_1_2_1_261_2","first-page":"L\u20101577","volume-title":"Dalbavancin phase 3 skin and skin structure studies: pathogens and microbiological efficacy [abstr]","author":"Goldstein BP","year":"2005"},{"key":"e_1_2_1_262_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2004.05.006"},{"key":"e_1_2_1_263_2","doi-asserted-by":"publisher","DOI":"10.1086\/427283"},{"key":"e_1_2_1_264_2","first-page":"L\u20101576","volume-title":"Safety of dalbavancin in a clinical development program [abstr]","author":"Seltzer E","year":"2005"},{"key":"e_1_2_1_265_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.1127-1134.2005"},{"key":"e_1_2_1_266_2","first-page":"C1","volume-title":"TD\u20106424, a novel rapidly bactericidal concentration\u2010dependent antibiotic, acts through a unique dual mode of action [abstr]","author":"Dabobov D","year":"2003"},{"key":"e_1_2_1_267_2","first-page":"C1","volume-title":"Effect of human serum on time\u2010kill curves, minimum inhibitory and bactericidal concentrations of TD\u20106424 against staphylococci and enterococci [abstr]","author":"Kaniga K","year":"2003"},{"key":"e_1_2_1_268_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.11.3602-3604.2003"},{"key":"e_1_2_1_269_2","first-page":"E\u20101747","volume-title":"Telavancin activity against current and diverse Staphylococcus aureus populations [abstr]","author":"Draghi DC","year":"2005"},{"key":"e_1_2_1_270_2","first-page":"F\u20102111","volume-title":"Evaluation of TD\u20106424 in the rabbit model of aortic valve endocarditis due to methicillin\u2010resistant Staphylococcus aureus or vancomycin\u2010intermediate Staphylococcus aureus [abstr]","author":"Basuino L","year":"2003"},{"key":"e_1_2_1_271_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.195-201.2005"},{"key":"e_1_2_1_272_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.3.862-867.2006"},{"key":"e_1_2_1_273_2","first-page":"E\u2010306","volume-title":"Antistaphylococcal kill kinetics of ceftobiprole and comparators [abstr]","author":"Ednie LM","year":"2005"},{"key":"e_1_2_1_274_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.884-888.2005"},{"key":"e_1_2_1_275_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2003.07.023"},{"key":"e_1_2_1_276_2","doi-asserted-by":"publisher","DOI":"10.1358\/dof.2004.029.03.785046"},{"key":"e_1_2_1_277_2","first-page":"L\u20101579","volume-title":"Efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections [abstr]","author":"Krievens D","year":"2005"},{"key":"e_1_2_1_278_2","unstructured":"U.S. National Institutes of Health.Clinical trials.gov. Available fromhttp:www.clinicaltrials.govshowNCT00303550. Accessed July 20 2006."},{"key":"e_1_2_1_279_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf098"},{"key":"e_1_2_1_280_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf100"},{"key":"e_1_2_1_281_2","first-page":"L\u20101572","volume-title":"Prospective, randomized, double\u2010blind, double\u2010dummy, multicenter comparative trial to evaluate the efficacy and safety of faropenem daloxate 300 mg PO BID for seven days vs co\u2010amoxiclav 625 mg PO TID for seven days in the treatment of uncomplicated skin and skin structure infections [abstr]","author":"Corrado M","year":"2005"},{"key":"e_1_2_1_282_2","first-page":"L\u20101571","volume-title":"Prospective, randomized, double\u2010blind, multicenter comparative trial to evaluate the efficacy and safety of faropenem daloxate 300 mg PO BID for seven days versus cephalexin 500 mg PO BID for seven days in the treatment of of uncomplicated skin and skin structure infections [abstr]","author":"Huck W","year":"2005"},{"key":"e_1_2_1_283_2","first-page":"48","article-title":"StaphVAX (Nabi)","volume":"3","author":"Jones T","year":"2002","journal-title":"Curr Opin Invest Drugs"},{"key":"e_1_2_1_284_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jp.7211496"},{"key":"e_1_2_1_285_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.959-962.2005"},{"key":"e_1_2_1_286_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00096-06"},{"key":"e_1_2_1_287_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011297"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.27.2.227","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.27.2.227","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:25:54Z","timestamp":1761053154000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.27.2.227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":286,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["10.1592\/phco.27.2.227"],"URL":"https:\/\/doi.org\/10.1592\/phco.27.2.227","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}